DO-BO

How should market access and medical affairs work together, Dr. Mike Rosenblatt? (Repost)

In this repost of MAP, the Market Access Podcast, from 15th of September 2023, you’ll hear from Dr Stefan Walzer and Dr Mike Rosenblatt as they’re discussing the age we are currently in of massive medical innovation, including a lot of new modalities especially in the area of ATMPs, and this insightful conversation highlights some core questions:

– What are the differences between Clinical Development and Medical Affairs?

– When should a company start telling their medical story about a new product?

– What are the differences between drugs and vaccinations from a medical affairs’ perspective?

– … and how should market access and medical affairs ideally work together?

Tune in to listen to the Market Access veteran Dr. Stefan Walzer and Dr. Mike Rosenblatt, one of the pioneers in Medical Affairs, Commercialisation and Market Access, as they continued their conversation from Boston, May 2023, through this epic podcast episode.

Related

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]

From Olympic ice to AI-powered leadership: What can Market Access teams learn from elite sports? In the 111+1 anniversary episode of MAP – the Market Access Podcast, Dr. Stefan Walzer interviews Livia Altmann, a former Swiss Olympic ice hockey player who has transitioned into a leadership and “Human Intelligence 2.0” expert. Together, they explore how […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world evidence and market access. Together they unpack how the UK NICE threshold increase (from £20–30k to £25–35k per QALY) and US reforms (IRA, MFN) are quietly […]